Michal Fishel Bartal1, Ashish Premkumar2, Madeline Murguia Rice3, Uma M Reddy4, Alan T N Tita5, Robert M Silver6, Yasser Y El-Sayed7, Ronald J Wapner8, Dwight J Rouse9, George R Saade10, John M Thorp11, Maged M Costantine12, Edward K Chien13, Brian M Casey14, Sindhu K Srinivas15, Geeta K Swamy16, Hyagriv N Simhan17. 1. University of Texas Health Science Center at Houston-Children's Memorial Hermann Hospital, Houston, Texas, USA. 2. Northwestern University, Chicago, Illinois, USA. 3. George Washington University Biostatistics Center, Washington, District of Columbia, USA. 4. Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut, USA. 5. Departments of Obstetrics and Gynecology of University of Alabama at Birmingham, Birmingham, Alabama, USA. 6. University of Utah Health Sciences Center, Salt Lake City, Utah, USA. 7. Stanford University, Stanford, California, USA. 8. Columbia University, New York, New York, USA. 9. Brown University, Providence, Rhode Island, USA. 10. University of Texas Medical Branch, Galveston, Texas, USA. 11. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 12. The Ohio State University, Columbus, Ohio, USA. 13. MetroHealth Medical Center-Case Western Reserve University, Cleveland, Ohio, USA. 14. University of Texas Southwestern Medical Center, Dallas, Texas, USA. 15. University of Pennsylvania, Philadelphia, Pennsylvania, USA. 16. Duke University, Durham, North Carolina, USA. 17. University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract
OBJECTIVE: To evaluate whether hypertensive disorders of pregnancy (HDP) among low-risk nulliparous women expectantly managed at or after 39 weeks of gestation are associated with adverse outcomes. DESIGN: Secondary analysis of a randomised trial. SETTING: Multicentre, USA. POPULATION: Individuals in the expectantly managed group who delivered on or after 39 weeks. METHODS: Multivariable analysis to estimate adjusted relative risks (aRR) for binomial outcomes, adjusted odds ratios (aOR) for multinomial outcomes and 95% CI. MAIN OUTCOME MEASURES: Composite adverse maternal outcome including placental abruption, pulmonary oedema, postpartum haemorrhage, postpartum infection, venous thromboembolism or intensive care unit admission. Secondary outcomes included a composite of perinatal death or severe neonatal complications, mode of delivery, small and large for gestational age and neonatal intermediate or intensive unit length of stay. RESULTS: Of the 3044 women randomised to expectant management in the original trial, 2718 (89.3%) were eligible for this analysis, of whom 373 (13.7%) developed HDP. Compared with participants who remained normotensive, those who developed HDP were more likely to experience the maternal composite (12% versus 6%, aRR 1.84, 95% CI 1.33-2.54) and caesarean delivery (29% versus 23%, aOR 1.32, 95% CI 1.01-1.71). Differences between the two groups were not significantly different for the adverse perinatal composite (7% versus 5%, aRR 1.38, 95% CI 0.92-2.07) or for other secondary outcomes. CONCLUSION: Almost 14% of low-risk nulliparous individuals expectantly managed at 39 weeks developed HDP, and were more likely to experience adverse maternal outcomes compared with those who did not develop HDP. TWEETABLE ABSTRACT: Almost 14% of low-risk nulliparous individuals expectantly managed at 39 weeks developed hypertensive disorders of pregnancy, and were more likely to experience adverse maternal outcomes compared with those who did not develop hypertensive disorders.
OBJECTIVE: To evaluate whether hypertensive disorders of pregnancy (HDP) among low-risk nulliparous women expectantly managed at or after 39 weeks of gestation are associated with adverse outcomes. DESIGN: Secondary analysis of a randomised trial. SETTING: Multicentre, USA. POPULATION: Individuals in the expectantly managed group who delivered on or after 39 weeks. METHODS: Multivariable analysis to estimate adjusted relative risks (aRR) for binomial outcomes, adjusted odds ratios (aOR) for multinomial outcomes and 95% CI. MAIN OUTCOME MEASURES: Composite adverse maternal outcome including placental abruption, pulmonary oedema, postpartum haemorrhage, postpartum infection, venous thromboembolism or intensive care unit admission. Secondary outcomes included a composite of perinatal death or severe neonatal complications, mode of delivery, small and large for gestational age and neonatal intermediate or intensive unit length of stay. RESULTS: Of the 3044 women randomised to expectant management in the original trial, 2718 (89.3%) were eligible for this analysis, of whom 373 (13.7%) developed HDP. Compared with participants who remained normotensive, those who developed HDP were more likely to experience the maternal composite (12% versus 6%, aRR 1.84, 95% CI 1.33-2.54) and caesarean delivery (29% versus 23%, aOR 1.32, 95% CI 1.01-1.71). Differences between the two groups were not significantly different for the adverse perinatal composite (7% versus 5%, aRR 1.38, 95% CI 0.92-2.07) or for other secondary outcomes. CONCLUSION: Almost 14% of low-risk nulliparous individuals expectantly managed at 39 weeks developed HDP, and were more likely to experience adverse maternal outcomes compared with those who did not develop HDP. TWEETABLE ABSTRACT: Almost 14% of low-risk nulliparous individuals expectantly managed at 39 weeks developed hypertensive disorders of pregnancy, and were more likely to experience adverse maternal outcomes compared with those who did not develop hypertensive disorders.
Authors: Kim Broekhuijsen; Gert-Jan van Baaren; Maria G van Pampus; Wessel Ganzevoort; J Marko Sikkema; Mallory D Woiski; Martijn A Oudijk; Kitty W M Bloemenkamp; Hubertina C J Scheepers; Henk A Bremer; Robbert J P Rijnders; Aren J van Loon; Denise A M Perquin; Jan M J Sporken; Dimitri N M Papatsonis; Marloes E van Huizen; Corla B Vredevoogd; Jozien T J Brons; Mesrure Kaplan; Anton H van Kaam; Henk Groen; Martina M Porath; Paul P van den Berg; Ben W J Mol; Maureen T M Franssen; Josje Langenveld Journal: Lancet Date: 2015-03-25 Impact factor: 79.321
Authors: C M W de Sonnaville; C W Hukkelhoven; F Vlemmix; H Groen; J M Schutte; B W Mol; M G van Pampus Journal: Ultrasound Obstet Gynecol Date: 2019-09-04 Impact factor: 7.299
Authors: Corine M Koopmans; Denise Bijlenga; Henk Groen; Sylvia Mc Vijgen; Jan G Aarnoudse; Dick J Bekedam; Paul P van den Berg; Karin de Boer; Jan M Burggraaff; Kitty Wm Bloemenkamp; Addy P Drogtrop; Arie Franx; Christianne Jm de Groot; Anjoke Jm Huisjes; Anneke Kwee; Aren J van Loon; Annemiek Lub; Dimitri Nm Papatsonis; Joris Am van der Post; Frans Jme Roumen; Hubertina Cj Scheepers; Christine Willekes; Ben Wj Mol; Maria G van Pampus Journal: Lancet Date: 2009-08-03 Impact factor: 79.321
Authors: Alan T N Tita; Lindsay Doherty; William A Grobman; Uma M Reddy; Robert M Silver; Gail Mallett; Madeline Murguia Rice; Yasser Y El-Sayed; Ronald J Wapner; Dwight J Rouse; George R Saade; John M Thorp; Suneet P Chauhan; Maged M Costantine; Edward K Chien; Brian M Casey; Sindhu K Srinivas; Geeta K Swamy; Hyagriv N Simhan; George A Macones Journal: Obstet Gynecol Date: 2021-02-01 Impact factor: 7.661